{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:06Z","timestamp":1761178566215,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.canrad.2019.07.131","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T08:21:09Z","timestamp":1565684469000},"page":"784-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personnalisation de la dose et du fractionnement de la radioth\u00e9rapie des cancers de la t\u00eate et du cou"],"prefix":"10.1016","volume":"23","author":[{"given":"P.","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Biau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.07.131_bib0255","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of Human papillomavirus-positive head neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/02841860802372272","article-title":"IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult","volume":"48","author":"Ho","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.radonc.2013.10.010","article-title":"Delineation of the neck node levels for head and neck tumors: a 2013\u00a0update DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines","volume":"110","author":"Gr\u00e9goire","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0270","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.canrad.2005.03.005","article-title":"Proposition de s\u00e9lection et d\u00e9limitation des volumes cibles microscopiques p\u00e9ritumoraux dans les cancers de la cavit\u00e9 buccale et de l\u2019oropharynx (aires ganglionnaires exclues)","volume":"9","author":"Lapeyre","year":"2005","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0275","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S1278-3218(10)70007-X","article-title":"Cancer de l\u2019hypopharynx et du larynx: proposition de s\u00e9lection et d\u00e9limitation des volumes cibles microscopiques p\u00e9ri-tumoraux (aires ganglionnaires exclues)","volume":"14","author":"Lapeyre","year":"2010","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0280","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.canrad.2016.07.002","article-title":"Radioth\u00e9rapie des cancers de la cavit\u00e9 buccale","volume":"20","author":"Lapeyre","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0285","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.canrad.2016.07.018","article-title":"Radioth\u00e9rapie des cancers du larynx","volume":"20Suppl","author":"Pointreau","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0290","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.canrad.2016.07.020","article-title":"Radioth\u00e9rapie des cancers de l\u2019hypopharynx","volume":"20","author":"Pointreau","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0295","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.canrad.2016.07.017","article-title":"Radioth\u00e9rapie des cancers de l\u2019oropharynx","volume":"20Suppl","author":"Servagi Vernat","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2019.07.131_bib0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2017.09.019","article-title":"Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy","volume":"126","author":"Hansen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","volume":"126","author":"Gr\u00e9goire","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.10.034","article-title":"Target volume selection and delineation (T and N) for primary radiation treatment of oral cavity, oropharyngeal, hypopharyngeal and laryngeal squamous cell carcinoma","volume":"87","author":"Gr\u00e9goire","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2019.01.018","article-title":"Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019\u00a0Update","volume":"134","author":"Biau","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","article-title":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0325","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/hed.20446","article-title":"Importance of patient examination to clinical quality assurance in head and neck radiation oncology","volume":"28","author":"Rosenthal","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.canrad.2019.07.131_bib0330","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijrobp.2016.11.019","article-title":"Prospective qualitative and quantitative analysis of real-time peer review quality assurance rounds incorporating direct physical examination for head and neck cancer radiation therapy","volume":"98","author":"Cardenas","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.131_bib0335","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0340","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijrobp.2017.01.018","article-title":"Re-evaluation of ipsilateral radiation for T1-T2N0-N2b tonsil carcinoma at the Princess Margaret Hospital in the HPV era, 25\u00a0years later","volume":"98","author":"Huang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.131_bib0345","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s10147-013-0650-6","article-title":"Sparing level Ib lymph nodes by intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma","volume":"19","author":"Chen","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0350","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2009.06.062","article-title":"Is elective irradiation to the lower neck necessary for N0\u00a0nasopharyngeal carcinoma?","volume":"77","author":"Gao","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.131_bib0355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93\u00a0randomised trials and 17,346, patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0360","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.radonc.2017.10.018","article-title":"Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project","volume":"126","author":"Lassen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0370","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-8140(92)90242-M","article-title":"Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy","volume":"25","author":"Horiot","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0375","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","article-title":"Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6\u00a0and 7\u00a0randomised controlled trial","volume":"362","author":"Overgaard","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2019.07.131_bib0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2009.04.082","article-title":"Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer","volume":"77","author":"Saunders","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.131_bib0385","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2006.08.057","article-title":"Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial","volume":"24","author":"Bourhis","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0390","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2019.07.131_bib0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.07.131_bib0400","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3\u00a0randomised trial","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.oraloncology.2018.05.007","article-title":"Smoking impact on HPV driven head and neck cancer's oncological outcomes?","volume":"82","author":"Mirghani","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0410","first-page":"4","article-title":"Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?","volume":"8","author":"Mirghani","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0415","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2019.07.131_bib0420","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3\u00a0trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2019.07.131_bib0425","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.prro.2018.10.015","article-title":"Reducing the radiation therapy dose prescription for elective treatment areas in human papillomavirus-associated oropharyngeal carcinoma being treated with primary chemoradiotherapy at Memorial Sloan Kettering Cancer Center","volume":"9","author":"Tsai","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0430","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in Human papillomavirus-associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0435","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdw051","article-title":"Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer","volume":"27","author":"Villaflor","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0440","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2\u00a0study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0445","first-page":"2271","article-title":"(18F)-fluoro-deoxy-glucose-positron emission tomography\/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis","volume":"50","author":"Rohde","year":"2014","journal-title":"Eur J Cancer 1990"},{"key":"10.1016\/j.canrad.2019.07.131_bib0450","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/jnci\/djn125","article-title":"(18F)-Fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis","volume":"100","author":"Kyzas","year":"2008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2019.07.131_bib0455","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2006.07.033","article-title":"Combined uptake of (18F)-FDG and (18F)-FMISO correlates with radiation therapy outcome in head-and-neck cancer patients","volume":"80","author":"Thorwarth","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0460","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0360-3016(00)00467-3","article-title":"Towards multidimensional radiotherapy (MD-CRT): biological imaging biological conformality","volume":"47","author":"Ling","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.07.131_bib0465","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.radonc.2011.06.020","article-title":"Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer","volume":"101","author":"Madani","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0470","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.109.069310","article-title":"(18F)-FLT PET\/CT for early response monitoring and dose escalation in oropharyngeal tumors","volume":"51","author":"Troost","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2019.07.131_bib0475","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1080\/0284186X.2017.1363910","article-title":"Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer","volume":"56","author":"M\u00f6nnich","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0480","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.critrevonc.2016.10.009","article-title":"Overview of the predictive value of quantitative (18F)-FDG PET in head and neck cancer treated with chemoradiotherapy","volume":"108","author":"Castelli","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0485","doi-asserted-by":"crossref","first-page":"20160768","DOI":"10.1259\/bjr.20160768","article-title":"The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective","volume":"90","author":"Wong","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0490","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-84","article-title":"Adaptive and innovative radiation treatment for improving cancer treatment outcome (Artforce); a randomized controlled phase II trial for individualized treatment of head and neck cancer","volume":"13","author":"Heukelom","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2019.07.131_bib0495","first-page":"19","article-title":"Magnetic resonance-based response assessment and dose adaptation in Human papilloma virus positive tumors of the oropharynx treated with radiotherapy (MR-adaptor): An R-Ideal stage 2a-2b\/Bayesian phase II trial","volume":"13","author":"Bahig","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2019.07.131_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.canrad.2019.07.147","article-title":"R\u00e9irradiations des carcinomes \u00e9pidermo\u00efdes des voies a\u00e9rodigestives sup\u00e9rieures\u00a0: indications et r\u00e9sultats","volume":"23","author":"Biau","year":"2019","journal-title":"Cancer Radiother"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819303051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:34:43Z","timestamp":1761136483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819303051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":50,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1278321819303051"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.131","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personnalisation de la dose et du fractionnement de la radioth\u00e9rapie des cancers de la t\u00eate et du cou","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.07.131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}